Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 75/100

Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

Key Takeaway: Insmed Incorporated will present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 10, 2024. The event will include a fireside chat that will be webcast live and available for 30 days afterward. Insmed is recognized for its commitment to treating patients with serious and rare diseases, highlighting its innovative therapies and pipelines, including advancements in artificial intelligence-driven protein engineering and gene therapy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed is actively presenting at a prestigious healthcare conference.
  • The company is focused on transforming the lives of patients with serious diseases.
  • Insmed has a robust pipeline targeting serious unmet medical needs.
  • The use of advanced technologies like AI in their research suggests innovation.

Full Press Release Details

BRIDGEWATER, N.J. , June 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024 , at 10:00 a.m. ET .
The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com . The webcast will be archived for a period of 30 days following the conclusion of the live event.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey , with additional offices and research locations throughout the United States , Europe , and Japan . Visit www.insmed.com to learn more.
Bryan Dunn Executive Director, Investor Relations Insmed (646) 812-4030 [email protected]
Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 [email protected]
Mandy Fahey Executive Director, Corporate Communications Insmed (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

When is Insmed's fireside chat scheduled?

The fireside chat is on June 10, 2024, at 10:00 a.m. ET.

How can I access the webcast of the fireside chat?

The webcast will be available in the investor relations section of Insmed's website.

What is Insmed's first commercial product?

Insmed's first product is a first-in-disease therapy for a chronic lung disease.

What types of diseases does Insmed focus on?

Insmed targets serious and rare diseases, including inflammatory and pulmonary disorders.

Where is Insmed headquartered?

Insmed is headquartered in Bridgewater, New Jersey.

Last updated: Jun 5, 2024